Maximilian von Eynatten
About
Maximilian von Eynatten is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology.
According to data from OpenAlex, Maximilian von Eynatten has authored 115 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Endocrinology, Diabetes and Metabolism, 43 papers in Surgery and 28 papers in Molecular Biology. Recurrent topics in Maximilian von Eynatten's work include Diabetes Treatment and Management (74 papers), Pancreatic function and diabetes (35 papers) and Diabetes Management and Research (31 papers). Maximilian von Eynatten is often cited by papers focused on Diabetes Treatment and Management (74 papers), Pancreatic function and diabetes (35 papers) and Diabetes Management and Research (31 papers). Maximilian von Eynatten collaborates with scholars based in Germany, United States and United Kingdom. Maximilian von Eynatten's co-authors include Odd Erik Johansen, Hans J. Woerle, Christoph Wanner, Bernard Zinman, Uli C. Broedl, Michaela Mattheus, Silvio E. Inzucchi, John M. Lachin, David Fitchett and Hans‐Juergen Woerle and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.
In The Last Decade
Maximilian von Eynatten
109 papers receiving 10.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Maximilian von Eynatten Germany | 44 | 8.2k | 3.5k | 3.2k | 2.0k | 1.6k | 115 | 11.0k | ||
| Guntram Schernthaner Austria | 60 | 6.2k 0.8× | 2.7k 0.8× | 2.9k 0.9× | 1.0k 0.5× | 1.4k 0.9× | 227 | 11.0k | ||
| Greg Fulcher Australia | 32 | 7.8k 1.0× | 3.4k 1.0× | 2.9k 0.9× | 1.1k 0.6× | 1.8k 1.2× | 65 | 9.5k | ||
| David Z.I. Cherney Canada | 55 | 10.7k 1.3× | 4.9k 1.4× | 3.6k 1.1× | 3.8k 1.9× | 2.9k 1.8× | 331 | 14.8k | ||
| Giancarlo Viberti United Kingdom | 62 | 6.6k 0.8× | 2.1k 0.6× | 3.7k 1.2× | 4.0k 2.0× | 3.8k 2.4× | 190 | 13.7k | ||
| Ingrid Gause‐Nilsson Sweden | 31 | 6.1k 0.8× | 2.5k 0.7× | 2.7k 0.8× | 648 0.3× | 1.7k 1.0× | 71 | 7.6k | ||
| Giorgio Sesti Italy | 67 | 6.9k 0.8× | 3.4k 1.0× | 5.6k 1.8× | 817 0.4× | 2.7k 1.7× | 416 | 15.1k | ||
| Adam Whaley‐Connell United States | 53 | 3.6k 0.4× | 1.7k 0.5× | 2.2k 0.7× | 2.5k 1.3× | 3.4k 2.1× | 217 | 10.4k | ||
| Vasilios G. Athyros Greece | 54 | 4.2k 0.5× | 3.9k 1.1× | 1.3k 0.4× | 1.1k 0.6× | 2.7k 1.7× | 285 | 10.5k | ||
| George Jerums Australia | 66 | 4.6k 0.6× | 1.3k 0.4× | 2.1k 0.7× | 4.8k 2.5× | 2.7k 1.7× | 285 | 13.4k | ||
| Samuel Dagogo‐Jack United States | 47 | 7.2k 0.9× | 2.6k 0.8× | 2.4k 0.8× | 395 0.2× | 1.1k 0.7× | 201 | 11.2k |
Countries citing papers authored by Maximilian von Eynatten
Since
Specialization
Citations
This map shows the geographic impact of Maximilian von Eynatten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maximilian von Eynatten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maximilian von Eynatten more than expected).
Fields of papers citing papers by Maximilian von Eynatten
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Maximilian von Eynatten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maximilian von Eynatten. The network helps show where Maximilian von Eynatten may publish in the future.
Co-authorship network of co-authors of Maximilian von Eynatten
This figure shows the co-authorship network connecting the top 25 collaborators of Maximilian von Eynatten. A scholar is included among the top collaborators of Maximilian von Eynatten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maximilian von Eynatten. Maximilian von Eynatten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Neeland, Ian J., Luiz Henrique de Gregório, Bo Åhrén, et al.. (2025). A Randomized, Placebo-Controlled, Single-Center, Crossover Study to Evaluate the Effects of Pre-Meal Whey Protein Microgel on Post-Prandial Glucometabolic and Amino Acid Response in People with Type 2 Diabetes and Overweight or Obesity. Metabolites. 15(1). 61–61.
2.
Mohamed, Mafauzy, Kalpana Bhaskaran, Joel Neutel, et al.. (2023). A Randomized, Placebo-Controlled Crossover Study to Evaluate Postprandial Glucometabolic Effects of Mulberry Leaf Extract, Vitamin D, Chromium, and Fiber in People with Type 2 Diabetes. Diabetes Therapy. 14(4). 749–766.
3.
Johansen, Odd Erik, Delphine Curti, Maximilian von Eynatten, et al.. (2023). Oligomalt, a New Slowly Digestible Carbohydrate, Is Well Tolerated in Healthy Young Men and Women at Intakes Up to 180 Gram per Day: A Randomized, Double-Blind, Crossover Trial. Nutrients. 15(12). 2752–2752.
4.
McGuire, Darren K., John H. Alexander, Odd Erik Johansen, et al.. (2019). Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 139(3). 351–361.
5.
Mayer, Gert, Christoph Wanner, Matthew R. Weir, et al.. (2019). Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney International. 96(2). 489–504.
6.
Wanner, Christoph, John M. Lachin, Silvio E. Inzucchi, et al.. (2017). Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 137(2). 119–129.
7.
C.W., Ronald, Stefano Del Prato, Baptist Gallwitz, et al.. (2017). Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial. Journal of Diabetes Investigation. 9(3). 579–586.
8.
Marx, Nikolaus, Vlado Perkovic, Hans‐Juergen Woerle, et al.. (2017). Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?. Diabetes Care. 40(9). 1144–1151.
9.
Cherney, David Z.I., Søren S. Lund, Bruce A. Perkins, et al.. (2016). The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 59(9). 1860–1870.
10.
Lehrke, Michael, Nikolaus Marx, Sanjay Patel, et al.. (2014). Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies. Clinical Therapeutics. 36(8). 1130–1146.
11.
Cherney, David Z.I., Bruce A. Perkins, Nima Soleymanlou, et al.. (2013). Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus. Circulation. 129(5). 587–597.
12.
Eynatten, Maximilian von, Yan Gong, Angela Emser, & Hans‐Juergen Woerle. (2013). Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovascular Diabetology. 12(1). 60–60.
13.
Barnett, Anthony, Holger Huisman, Russell Jones, et al.. (2013). Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. The Lancet. 382(9902). 1413–1423.
14.
Prato, Stefano Del, Marja‐Riitta Taskinen, David R. Owens, et al.. (2013). Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials. Journal of Diabetes and its Complications. 27(3). 274–279.
15.
Eynatten, Maximilian von, Lutz Philipp Breitling, Marcel Roos, et al.. (2012). Circulating Adipocyte Fatty Acid-Binding Protein Levels and Cardiovascular Morbidity and Mortality in Patients With Coronary Heart Disease. Arteriosclerosis Thrombosis and Vascular Biology. 32(9). 2327–2335.
16.
Johansen, Odd Erik, Dietmar Neubacher, Maximilian von Eynatten, Sanjay Patel, & Hans‐Juergen Woerle. (2012). Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovascular Diabetology. 11(1). 3–3.
17.
Cheng, Pan, Christoph Schmaderer, Marcel Roos, et al.. (2011). Comparing aortic stiffness in kidney transplant recipients, hemodialysis patients, and patients with chronic renal failure. Clinical Transplantation. 25(4). E463–8.
18.
Eynatten, Maximilian von, Philipp M. Lepper, D. Liu, et al.. (2007). Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia. 50(9). 1930–1937.
19.
Lepper, Philipp M., Christian Schumann, Kathy Triantafilou, et al.. (2007). Association of Lipopolysaccharide-Binding Protein and Coronary Artery Disease in Men. Journal of the American College of Cardiology. 50(1). 25–31.
20.
Rudofsky, Gottfried, Andrea Schlotterer, Maximilian von Eynatten, et al.. (2004). No association of the 94T/G polymorphism in the adiponectin gene with diabetic complications. Diabetes Obesity and Metabolism. 7(4). 455–459.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Guntram Schernthaner Breakdown of academic impact, for papers by Greg Fulcher Breakdown of academic impact, for papers by David Z.I. Cherney Breakdown of academic impact, for papers by Giancarlo Viberti Breakdown of academic impact, for papers by Ingrid Gause‐Nilsson Breakdown of academic impact, for papers by Giorgio Sesti Breakdown of academic impact, for papers by Adam Whaley‐Connell Breakdown of academic impact, for papers by Vasilios G. Athyros Breakdown of academic impact, for papers by George Jerums Breakdown of academic impact, for papers by Samuel Dagogo‐Jack